Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388551 | 0.86 | GPR119 (0.59) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2394364 | 0.83 | GPR119 (0.42) | GPR119GPR183 | |
| SCHEMBL2372132 | 0.83 | GPR119 (0.79) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL1713233 | 0.82 | GPR119 (0.62) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL121348 | 0.82 | GPR119 (0.52) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL1713416 | 0.82 | GPR119 (0.55) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2371526 | 0.81 | GPR119 (0.61) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL12356432 | 0.81 | GPR119 (0.62) | GPR119GPR183KCNH2 | |
| SCHEMBL15109960 | 0.81 | GPR119 (0.50) | GPR119GPR183CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2399035 | 0.80 | GPR119 (0.71) | GPR119GPR183CYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074838-B | Compound having GPR119 agonist activity, method for preparing the same, and pharmaceutical composition comprising the same as an effective ingredient | 东亚ST株式会社 | 2021-03-19 | — | — | CN | disclosed |
| EP-3212640-B1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG A ST CO LTD (KR) | 2019-11-06 | — | — | EP | disclosed |
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | 2019-10-01 | — | — | US | disclosed |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| EP-3212640-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | Dong-A ST Co., Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016068453-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016068453-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2318399-B1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| WO-2010004346-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004346-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004344-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | GPR119, GPR84, GPR88 | GPR119 1/4885GPR183 38/4885CYP3A4 813/4885 |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | GPR119, FFAR2, GCGR | GPR119 1/4885GPR183 30/4885CYP3A4 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.